Mark G. Swain MD, MSc, FRCPC, FAASLD, FCAHSCal Wenzel Family Foundation Chair in Hepatology, Professor of Medicine, and Head, Division of Gastroenterology and Hepatology, University of Calgary; Section Head, Section of Gastroenterology and Hepatology, Calgary Zone, Alberta Health Services, Calgary, Alberta, Canada
Dr. Mark Swain is Professor of Medicine and Head of the Division of Gastroenterology and Hepatology at the University of Calgary, Alberta, Canada. He currently holds the Cal Wenzel Family Foundation Chair in Hepatology. Dr. Swain is a clinician-scientist with a basic science research interest focused on how liver diseases causes symptoms such as fatigue. His clinical interests are focused in the areas of quality improvement and wait time reduction strategies, and his clinical research interests involve studying fatty liver disease (NAFLD), primary biliary cirrhosis, autoimmune hepatitis and eradicating hepatitis C.
DisclosuresDr. Swain reports the following:
- Advisory board: Gilead, Intercept, Novartis
- Speaker: Gilead, Intercept, Abbott
- Clinical trial or research support: Gilead, BMS, CymaBay, Intercept, Genfit, Pfizer, Novartis, Astra Zeneca, GSK, Celgene, Novo Nordisk, Axcella Health Inc., Merck, Galectin Therapeutics